Supply Chain Crisis, Not Tariffs, Stoked Inflation
Don’t blame the China tariffs on inflation. Supply chain snafus were a much bigger deal, a Federal Reserve report says.
Katherine Tai Says Globalization No Longer Sustainable
At National Press Club, Katherine Tai talks about supply chain issues, what ‘de-risking’ from China might look like, and how USTR thinks about it.
CPA Applauds Bicameral Bill Targeting De Minimis, the ‘China Free Trade’ Loophole
The House and Senate join forces to remove China, others, from the duty-free ‘de minimis’ import rule.
CPA Applauds Senators Cassidy, Baldwin and Vance for Bill to Limit Damage of “De Minimis” Import Loophole
Three Senators going after China’s “free trade” deal with the United States.
Congress Should Compel Global Divestment from China’s Slave Labor
Creating a stark choice between American investment and forced labor operations is the best way to combat modern slavery in China. Public opinion of China
CPA Applauds House Bill Seeking to Ban Securities of Foreign Adversaries from Private Pension Plans
The Coalition for a Prosperous America (CPA) today applauded a new bill by Rep. Jim Banks (R-IN-03) that would ban private pension plans from investing
FDA Allows Uninspected China Lab to Sell Cancer Drugs in the US
A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?
House Hearing on Dollar Focused on Sanctions Powers, ‘De-Dollarization’ Risks
The House Financial Services Committee says American consumers are helped by a strong dollar, which lowers the price of imports to the tune of up to $45 billion per year in savings. In a $23 trillion economy, is an overvalued dollar really worth it?
U.S. Trade Deficit Rises 23% in April; Goods Gap Breaks Record For Year
China as a source for American imports is on the wane thanks to tariffs, other business risks. But strong dollar keeps imports booming.
To Fight Drug Shortages FDA Has an Idea: Import More Inspection-Free Drugs
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
